Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CX 516

Drug Profile

CX 516

Alternative Names: 1-BCP; Ampakine CX 516; AMPAlex; BDP-12; SPD 420

Latest Information Update: 14 May 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cortex Pharmaceuticals
  • Class Piperidines
  • Mechanism of Action AMPA receptor agonists; AMPA receptor antagonists; Glutamate agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Autistic disorder; Mild cognitive impairment; Schizophrenia; Sleep disorders; Stroke

Most Recent Events

  • 11 Oct 2004 Two studies have been added to the adverse events and Psychotic disorders therapeutic trials sections ,
  • 01 Jul 2004 Phase-II clinical trials in Sleep disorders in USA (unspecified route)
  • 20 Feb 2004 Data from a media release have been added to the Alzheimer's disease and Cognitive disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top